McKay, R.De Velasco, G.Werner, L.Bellmunt, J.Harshman, L.Sweeney, C.Rosenberg, J.Hirsch, M.Signoretti, S.Van Allen, E.Walsh, M.Vaishampayan, U.McDermott, D.Choueiri, T.2017-07-032017-07-032016Cancer, 2016; 122(15):2389-23980008-543X1097-0142http://hdl.handle.net/2440/106367Abstract not availableen© 2016 American Cancer SocietyBevacizumab; buparlisib; phase 1; phosphatidylinositol-3 kinase (PI3K) inhibitor; renal cell carcinomaA phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapiesJournal article003004930810.1002/cncr.300560003800588000152-s2.0-85003653158251762Sweeney, C. [0000-0002-0398-6018]